Skip to main content
. Author manuscript; available in PMC: 2019 Dec 15.
Published in final edited form as: Clin Cancer Res. 2018 Aug 20;24(24):6408–6420. doi: 10.1158/1078-0432.CCR-17-3265

Figure 5. Expression of c-Myc in R191-treated cells.

Figure 5.

The impact of R191 treatment for 24 hours on BCWM.1 and MWCL-1 cells was studied at the mRNA level using quantitative real-time PCR (A), and at the protein level by Western blot analysis (B). Data in A are expressed as the means ± SD for samples assayed in triplicates, and “*” indicates p-values <0.003, while “**” indicates p-values ≤0.0003.Expression of c-Myc was suppressed in BCWM.1 cells using two different shRNAs (designated 1–1 and 2–5 in (C)), and these were then treated with R191 and viability was studies with the WST-1 assay (D) and compared with a non-targeting (NT) control. Data are expressed as the means ± SD for samples assayed in triplicates, and “*” indicates p-values ≤0.0001.Two loss-of-function IRAK4 mutants were expressed in BCWM.1 cells, exposed to the indicated concentrations of R191 for 72 hours, and the viability was then determined and expressed as detailed above, and compared to control cells and cells with wild-type (WT) IRAK4 (E). Western blotting was then performed to evaluate the impact of these mutants on downstream targets of interest (F).